Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT04222972 |
Title | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) |
Recruitment | Recruiting |
Gender | both |
Phase | Phase III |
Variant Requirements | Yes |
Sponsors | Blueprint Medicines Corporation |
Indications | |
Therapies |
Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Cisplatin + Pemetrexed Disodium |
Age Groups: | senior | adult |
Covered Countries | USA | ITA | FRA | ESP | DEU | CAN | BEL |